EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand

EnPlusOne, a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, revealed today that it had achieved the successful synthesis of the antisense strand of the commercially approved siRNA drug, Leqvio^® (inclisiran), a treatment for hypercholesteremia (high-cholesterol). Licensed from Alnylam Pharmaceuticals, Inc. by Novartis, Leqvio^® currently addresses a multi-million patient population.